MovDisordV3, Main, Exploration, bibRecord, 002C45

Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease

Identifieur interne : 002C45 ( Main/Exploration ); précédent : 002C44; suivant : 002C46

Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease

Auteurs : Francesc Valldeoriola [Espagne] ; Ossama Morsi [Espagne] ; Eduardo Tolosa [Espagne] ; Jordi Rumià [Espagne] ; Maria José Martí [Espagne] ; Pablo Martínez-Martín [Espagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2007-11-15.

RBID : ISTEX:AA145911C0E78474945B5EDF22BB43F94277DD1F

Descripteurs français

Pascal (Inist)
- Analyse coût efficacité, Chimiothérapie, Coût, Etude comparative, Maladie de Parkinson, Pathologie du système nerveux, Prospective, Stade avancé.
Wicri :
- geographic : Espagne.
- topic : Prospective.

English descriptors

KwdEn :
- Advanced stage, Aged, Benchmarking, Chemotherapy, Comparative study, Cost efficiency analysis, Cost of Illness, Cost-Benefit Analysis, Costs, Deep Brain Stimulation (economics), Female, Health Expenditures, Health Services (utilization), Humans, Male, Middle Aged, Nervous system diseases, Parkinson Disease (economics), Parkinson Disease (therapy), Parkinson disease, Prospective, Prospective Studies, QALY, Quality of Life, Questionnaires, Sensitivity and Specificity, Spain, Subthalamic Nucleus, cost‐efficacy, expenses, subthalamic stimulation.
MESH :
- geographic : Spain.
- economics : Deep Brain Stimulation, Parkinson Disease.
- therapy : Parkinson Disease.
- utilization : Health Services.
- Aged, Benchmarking, Cost of Illness, Cost-Benefit Analysis, Female, Health Expenditures, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Questionnaires, Sensitivity and Specificity, Subthalamic Nucleus.

Abstract

This is an open, prospective, longitudinal study designed to compare two cohorts of patients with advanced Parkinson's disease during 1 year, one undergoing bilateral subthalamic stimulation (STN‐DBS) and the other receiving the best medical treatment (BMT), with respect to the clinical effects observed and the medical expenses produced. Assessments were done by using clinical measures and a generic health related quality of life scale. A questionnaire was used to collect direct healthcare resources. As a measure of cost‐effectiveness, we calculated life years gained adjusted by health‐related quality of life (QALY) and the incremental cost‐effectiveness ratio (ICER). Clinical and demographic variables of both groups were comparable at baseline. Total UPDRS scores improved from 50.5 ± 3.6 to 28.5 ± 3.8 in STN‐DBS patients and worsened from 44.3 ± 3.3 to 54.2 ± 4 in the control group. Pharmacological costs in the operated patients were 3,799 ± 940€, while in the BMT group the costs were 13,208 ± 4,966€. Other medical costs were 1,280 ± 720€ in the STN‐DBS group and 4,017 ± 2,962€ in BMT patients. Nondirect medical costs were 4,079 ± 1,289 in operated patients and 2,787 ± 1,209€ in the BMT group. Mean QALYs were 0.7611 ± 0.03 in STN‐DBS and 0.5401 ± 0.06 in BMT patients. In STN‐DBS patients, the ICER needed to obtain an improvement of one point in the total UPDRS score was of 239.8€ and the ICER/QALY was of 34,389€. Cost‐effectiveness parameters were mostly related to the degree of clinical improvement and the reduction of pharmacological costs after STN‐DBS. An ICER of 34,389€/QALY is within appropriate limits to consider subthalamic stimulation as an efficient therapy. © 2007 Movement Disorder Society

Url:

https://api.istex.fr/document/AA145911C0E78474945B5EDF22BB43F94277DD1F/fulltext/pdf

DOI: 10.1002/mds.21652

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease</title>
<author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name>
</author>
<author><name sortKey="Morsi, Ossama" sort="Morsi, Ossama" uniqKey="Morsi O" first="Ossama" last="Morsi">Ossama Morsi</name>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
</author>
<author><name sortKey="Rumia, Jordi" sort="Rumia, Jordi" uniqKey="Rumia J" first="Jordi" last="Rumià">Jordi Rumià</name>
</author>
<author><name sortKey="Marti, Maria Jose" sort="Marti, Maria Jose" uniqKey="Marti M" first="Maria José" last="Martí">Maria José Martí</name>
</author>
<author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martínez-Martín">Pablo Martínez-Martín</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AA145911C0E78474945B5EDF22BB43F94277DD1F</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21652</idno>
<idno type="url">https://api.istex.fr/document/AA145911C0E78474945B5EDF22BB43F94277DD1F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000322</idno>
<idno type="wicri:Area/Istex/Curation">000322</idno>
<idno type="wicri:Area/Istex/Checkpoint">001753</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Valldeoriola F:prospective:comparative:study</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17724747</idno>
<idno type="wicri:Area/PubMed/Corpus">002535</idno>
<idno type="wicri:Area/PubMed/Curation">002535</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002616</idno>
<idno type="wicri:Area/Ncbi/Merge">001E24</idno>
<idno type="wicri:Area/Ncbi/Curation">001E24</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001E24</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Valldeoriola F:prospective:comparative:study</idno>
<idno type="wicri:Area/Main/Merge">003B67</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0071403</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001458</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001861</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001512</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Valldeoriola F:prospective:comparative:study</idno>
<idno type="wicri:Area/Main/Merge">004102</idno>
<idno type="wicri:Area/Main/Curation">002C45</idno>
<idno type="wicri:Area/Main/Exploration">002C45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease</title>
<author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinic, Institut de Neurociències Universitat de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morsi, Ossama" sort="Morsi, Ossama" uniqKey="Morsi O" first="Ossama" last="Morsi">Ossama Morsi</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinic, Institut de Neurociències Universitat de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinic, Institut de Neurociències Universitat de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rumia, Jordi" sort="Rumia, Jordi" uniqKey="Rumia J" first="Jordi" last="Rumià">Jordi Rumià</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinic, Institut de Neurociències Universitat de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marti, Maria Jose" sort="Marti, Maria Jose" uniqKey="Marti M" first="Maria José" last="Martí">Maria José Martí</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinic, Institut de Neurociències Universitat de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martínez-Martín">Pablo Martínez-Martín</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institute of Health Carlos III, National Center for Epidemiology, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-11-15">2007-11-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">15</biblScope>
<biblScope unit="page" from="2183">2183</biblScope>
<biblScope unit="page" to="2191">2191</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">AA145911C0E78474945B5EDF22BB43F94277DD1F</idno>
<idno type="DOI">10.1002/mds.21652</idno>
<idno type="ArticleID">MDS21652</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Aged</term>
<term>Benchmarking</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Cost efficiency analysis</term>
<term>Cost of Illness</term>
<term>Cost-Benefit Analysis</term>
<term>Costs</term>
<term>Deep Brain Stimulation (economics)</term>
<term>Female</term>
<term>Health Expenditures</term>
<term>Health Services (utilization)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (economics)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Prospective</term>
<term>Prospective Studies</term>
<term>QALY</term>
<term>Quality of Life</term>
<term>Questionnaires</term>
<term>Sensitivity and Specificity</term>
<term>Spain</term>
<term>Subthalamic Nucleus</term>
<term>cost‐efficacy</term>
<term>expenses</term>
<term>subthalamic stimulation</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="utilization" xml:lang="en"><term>Health Services</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Benchmarking</term>
<term>Cost of Illness</term>
<term>Cost-Benefit Analysis</term>
<term>Female</term>
<term>Health Expenditures</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Quality of Life</term>
<term>Questionnaires</term>
<term>Sensitivity and Specificity</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Analyse coût efficacité</term>
<term>Chimiothérapie</term>
<term>Coût</term>
<term>Etude comparative</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Prospective</term>
<term>Stade avancé</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This is an open, prospective, longitudinal study designed to compare two cohorts of patients with advanced Parkinson's disease during 1 year, one undergoing bilateral subthalamic stimulation (STN‐DBS) and the other receiving the best medical treatment (BMT), with respect to the clinical effects observed and the medical expenses produced. Assessments were done by using clinical measures and a generic health related quality of life scale. A questionnaire was used to collect direct healthcare resources. As a measure of cost‐effectiveness, we calculated life years gained adjusted by health‐related quality of life (QALY) and the incremental cost‐effectiveness ratio (ICER). Clinical and demographic variables of both groups were comparable at baseline. Total UPDRS scores improved from 50.5 ± 3.6 to 28.5 ± 3.8 in STN‐DBS patients and worsened from 44.3 ± 3.3 to 54.2 ± 4 in the control group. Pharmacological costs in the operated patients were 3,799 ± 940€, while in the BMT group the costs were 13,208 ± 4,966€. Other medical costs were 1,280 ± 720€ in the STN‐DBS group and 4,017 ± 2,962€ in BMT patients. Nondirect medical costs were 4,079 ± 1,289 in operated patients and 2,787 ± 1,209€ in the BMT group. Mean QALYs were 0.7611 ± 0.03 in STN‐DBS and 0.5401 ± 0.06 in BMT patients. In STN‐DBS patients, the ICER needed to obtain an improvement of one point in the total UPDRS score was of 239.8€ and the ICER/QALY was of 34,389€. Cost‐effectiveness parameters were mostly related to the degree of clinical improvement and the reduction of pharmacological costs after STN‐DBS. An ICER of 34,389€/QALY is within appropriate limits to consider subthalamic stimulation as an efficient therapy. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Catalogne</li>
<li>Communauté de Madrid</li>
</region>
<settlement><li>Barcelone</li>
<li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Catalogne"><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name>
</region>
<name sortKey="Marti, Maria Jose" sort="Marti, Maria Jose" uniqKey="Marti M" first="Maria José" last="Martí">Maria José Martí</name>
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martínez-Martín">Pablo Martínez-Martín</name>
<name sortKey="Morsi, Ossama" sort="Morsi, Ossama" uniqKey="Morsi O" first="Ossama" last="Morsi">Ossama Morsi</name>
<name sortKey="Rumia, Jordi" sort="Rumia, Jordi" uniqKey="Rumia J" first="Jordi" last="Rumià">Jordi Rumià</name>
<name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C45 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C45 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:AA145911C0E78474945B5EDF22BB43F94277DD1F
   |texte=   Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease

Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.